The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.

The tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-pr...

Full description

Bibliographic Details
Main Authors: Thomas Gevaert, Yves-Rémi Van Eycke, Thomas Vanden Broeck, Hein Van Poppel, Isabelle Salmon, Sandrine Rorive, Tim Muilwijk, Frank Claessens, Dirk De Ridder, Steven Joniau, Christine Decaestecker
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0244663
id doaj-ec82bfb8bd3541ba89838661fe6c91c8
record_format Article
spelling doaj-ec82bfb8bd3541ba89838661fe6c91c82021-03-23T05:31:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-011512e024466310.1371/journal.pone.0244663The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.Thomas GevaertYves-Rémi Van EyckeThomas Vanden BroeckHein Van PoppelIsabelle SalmonSandrine RoriveTim MuilwijkFrank ClaessensDirk De RidderSteven JoniauChristine DecaesteckerThe tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-prostatectomy. Tissue micro-arrays (TMA) were composed with both prostate non-tumour (PNT) and PCa tissue and subsequently processed for immunohistochemistry (IHC). The IHC panel included markers for cancer activated fibroblasts (CAFs), blood vessels and steroid hormone receptors ((SHR): androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER)). Stained slides were digitalised, selectively annotated and analysed for percentage of marker expression with standardized and validated image analysis algorithms. A univariable analysis identified several TME markers with significant impact on CR: expression of CD31 (vascular marker) in PNT stroma, expression of alpha smooth muscle actin (αSMA) in PCa stroma, and PR expression ratio between PCa stroma and PNT stroma. A multivariable model, which included CD31 expression (vascular marker) in PNT stroma and PR expression ratio between PCa stroma and PNT stroma, could significantly stratify patients for CLR, with the identification of a low risk and high-risk subgroup. If validated and confirmed in an independent prospective series, this subgroup might have clinical potential for PCa patient stratification.https://doi.org/10.1371/journal.pone.0244663
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Gevaert
Yves-Rémi Van Eycke
Thomas Vanden Broeck
Hein Van Poppel
Isabelle Salmon
Sandrine Rorive
Tim Muilwijk
Frank Claessens
Dirk De Ridder
Steven Joniau
Christine Decaestecker
spellingShingle Thomas Gevaert
Yves-Rémi Van Eycke
Thomas Vanden Broeck
Hein Van Poppel
Isabelle Salmon
Sandrine Rorive
Tim Muilwijk
Frank Claessens
Dirk De Ridder
Steven Joniau
Christine Decaestecker
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
PLoS ONE
author_facet Thomas Gevaert
Yves-Rémi Van Eycke
Thomas Vanden Broeck
Hein Van Poppel
Isabelle Salmon
Sandrine Rorive
Tim Muilwijk
Frank Claessens
Dirk De Ridder
Steven Joniau
Christine Decaestecker
author_sort Thomas Gevaert
title The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
title_short The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
title_full The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
title_fullStr The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
title_full_unstemmed The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
title_sort potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2020-01-01
description The tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-prostatectomy. Tissue micro-arrays (TMA) were composed with both prostate non-tumour (PNT) and PCa tissue and subsequently processed for immunohistochemistry (IHC). The IHC panel included markers for cancer activated fibroblasts (CAFs), blood vessels and steroid hormone receptors ((SHR): androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER)). Stained slides were digitalised, selectively annotated and analysed for percentage of marker expression with standardized and validated image analysis algorithms. A univariable analysis identified several TME markers with significant impact on CR: expression of CD31 (vascular marker) in PNT stroma, expression of alpha smooth muscle actin (αSMA) in PCa stroma, and PR expression ratio between PCa stroma and PNT stroma. A multivariable model, which included CD31 expression (vascular marker) in PNT stroma and PR expression ratio between PCa stroma and PNT stroma, could significantly stratify patients for CLR, with the identification of a low risk and high-risk subgroup. If validated and confirmed in an independent prospective series, this subgroup might have clinical potential for PCa patient stratification.
url https://doi.org/10.1371/journal.pone.0244663
work_keys_str_mv AT thomasgevaert thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT yvesremivaneycke thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT thomasvandenbroeck thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT heinvanpoppel thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT isabellesalmon thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT sandrinerorive thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT timmuilwijk thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT frankclaessens thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT dirkderidder thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT stevenjoniau thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT christinedecaestecker thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT thomasgevaert potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT yvesremivaneycke potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT thomasvandenbroeck potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT heinvanpoppel potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT isabellesalmon potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT sandrinerorive potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT timmuilwijk potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT frankclaessens potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT dirkderidder potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT stevenjoniau potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
AT christinedecaestecker potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients
_version_ 1714769348081483776